Claims for Patent: 7,645,460

Summary for Patent: 7,645,460

Title:	Dosage forms of risedronate
Abstract:	Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Inventor(s):	Dansereau; Richard John (Cincinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	11/286,875
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,645,460
Patent Claims:	1. An oral dosage form having pharmaceutically effective absorption comprising: (a) from about about 1 mg to about 250 mg of a bisphosphonate selected from the group consisting of risedronate and acids, salts, and esters thereof; (b) from about 10 mg to about 500 mg of EDTA; and (c) a delayed release mechanism to immediately release the risedronate and the EDTA in the small intestine; wherein said composition weighs no greater than 1 gram. 2. The oral dosage form of claim 1 wherein the EDTA is disodium EDTA. 3. The oral dosage form of claim 1 wherein the delayed release mechanism is selected from the group consisting of pH triggered delivery systems, time dependent delivery systems and mixtures thereof. 4. The oral dosage form of claim 3 wherein the delayed release mechanism is a pH triggered delivery system. 5. The oral dosage form of claim 4 wherein the pH triggered delivery system comprises an enteric coating. 6. The oral dosage form of claim 5 wherein the enteric coating disintegrates between about pH 5.5 and about pH 6.5. 7. The oral dosage of claim 5 which comprises from about 75 mg to about 250 mg of EDTA, wherein the EDTA is disodium EDTA. 8. An oral dosage form having pharmaceutically effective absorption comprising: (a) from about 1 mg to about 250 mg risedronate sodium; (b) from about 25 mg to about 500 mg of disodium EDTA; and (c) an enteric coating which provides for immediate release of the risedronate sodium and the disodium EDTA in the small intestine of a mammal. 9. The oral dosage form of claim 8 comprising from about 35 mg to about 50 mg of the risedronate sodium. 10. A method for treating a disease selected from the group consisting of osteoporosis, Paget's disease, hyperparathyroidism, hypercalcemia of malignancy, osteolytic bone metastasis, and combinations thereof, comprising administering to a human or other mammal in need thereof a safe and effective amount of the oral dosage form of claim 1. 11. The method of claim 10 wherein the disease is osteoporosis. 12. The method of claim 11 wherein the oral dosage form is administered according to a continuous schedule having a dosing interval selected from the group consisting of daily, weekly, three times per month, twice monthly, and once monthly. 13. The method of claim 12 wherein the oral dosage form is administered weekly. 14. The method of claim 10 wherein the oral dosage form is administered with or without food. 15. The oral dosage form of claim 8 comprising from about 15 mg to about 55 mg of the risedronate sodium. 16. The oral dosage form of claim 15 comprising from about 75 mg to about 250 mg of the disodium EDTA. 17. The oral dosage form of claim 16 comprising about 35 mg of the risedronate sodium. 18. The oral dosage form of claim 17 wherein the enteric coating is a methacrylic acid copolymer. 19. The oral dosage form of claim 17 comprising about 100 mg of the disodium EDTA. 20. The oral dosage form of claim 19 wherein the enteric coating is a methacrylic acid copolymer. 21. The oral dosage form of claim 8 comprising from about 50 mg to about 280 mg of the risedronate sodium. 22. The oral dosage form of claim 21 comprising from about 75 mg to about 250 mg of the disodium EDTA. 23. The oral dosage form of claim 22 comprising about 150 mg of the risedronate sodium. 24. The oral dosage form of claim 23 wherein the enteric coating is a methacrylic acid copolymer. 25. The oral dosage form of claim 23 comprising about 100 mg of the disodium EDTA. 26. The oral dosage form of claim 25 wherein the enteric coating is a methacrylic acid copolymer. 27. A method for treating osteoporosis comprising administering to a human or other mammal in need thereof a safe and effective amount of the oral dosage form of claim 17. 28. The method of claim 27 wherein the oral dosage form is administered with or without food. 29. A method for treating osteoporosis comprising administering to a human or other mammal in need thereof a safe and effective amount of the oral dosage form of claim 25. 30. The method of claim 29 wherein the oral dosage form is administered with or without food.